Increased prevalence of factor V Leiden in patients with retinal vein occlusion and under 60 years of age

Summary

Retinal vein occlusion (RVO) is a multifactorial disease involving vessel damage, stasis, viscosity and thrombosis. Conflicting findings on hereditary thrombophilic risk factors have been reported and their impact on RVO features remains to be defined. The aim of the present study was to evaluate the prevalence of hereditary thrombophilic risk factors (HTRF) and characteristics of RVO in patients with or without HTRF. The design of the study was a prospective, observational case series. Two hundred and thirty-four patients with RVO were included consecutively. A French healthy population of the same region was studied as control group. The HTRF studied were protein C (PC), protein S (PS) and antithrombin (AT) deficiencies, factor V Leiden (FVL) and factor II 20210A polymorphisms. Chi-Square was used for comparison with the healthy subjects and between RVO patient with and without HTRF according to localisation (branch vs. central), type of RVO (ischemic or non-ischemic), recurrence, age at first event and classical vascular risk factors. Twenty-two patients had HTRF (12 FV Leiden heterozygotes, 9 FII 20210A heterozygotes and 1 PS deficiency). No AT or PC deficiency was detected. Frequencies of PS deficiency, FVL and FII 20210A allele were similar to the reference population as well as to published data in the general caucasian population. Eighty-six patients experienced their first episode before the age of 60 years. Systemic hypertension, glaucoma and angina were significantly less frequent in patients with RVO before 60 years. Fourteen of the 22 patients with one HTRF (64%) experienced their first episode of RVO before the age of 60 years compared to 72 of 212 without HTRF (34%) (p = 0.006). Heterozygote status for FV Leiden was significantly more frequent in patients who had experienced their first episode of RVO before 60 years (p = 0.027). In conclusion, this study suggests a role of FV Leiden in the occurrence of RVO in patients younger than 60 years who exhibit fewer acquired vascular risk factors than in older patients.

Keywords

Retinal vein occlusion - Factor V Leiden - hereditary thrombosis risk factors

• References

• 1 Risk factors for central retinal vein occlusion. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1996; 114: 545-54.
• 2 Arsene S, Giraudeau B, Le Lez ML. et al. Follow up by colour Doppler imaging of 102 patients with retinal vein occlusion over 1 year. Br J Ophthalmol 2002; 86: 1243-7.
• 3 Tranquart F, Arsene S, Giraudeau B. et al. Initial color Doppler findings in retinal vein occlusion. J Clin Ultrasound 2000; 28: 28-33.
• 4 Fegan CD. Central retinal vein occlusion and thrombophilia. Eye 2002; 16: 98-106.
• 5 Tranquart F, Arsene S, Aubert-Urena AS. et al. Doppler assessment of hemodynamic changes after hemodilution in retinal vein occlusion. J Clin Ultrasound 1998; 26: 119-24.
• 6 Weger M, Stanger O, Deutschmann H. et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 286-90.
• 7 Lahey JM, Kearney JJ, Tunc M. Hypercoagulable states and central retinal vein occlusion. Curr Opin Pulm Med 2003; 9: 385-92.
• 8 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
• 9 Hansen LL, Wiek J, Wiederholt M. A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution. Br J Ophthalmol 1989; 73: 895-9.
• 10 Chen HC, Wiek J, Gupta A. et al. Effect of isovolaemic haemodilution on visual outcome in branch retinal vein occlusion. Br J Ophthalmol 1998; 82: 162-7.
• 11 Ripoll L, Paulin D, Thomas S. et al. Multiplex PCRmediated site-directed mutagenesis for one-step determination of factor V Leiden and G20210A transition of the prothrombin gene. Thromb Haemost 1997; 78: 960-1.
• 12 Prisco D, Marcucci R, Bertini L. et al. Cardiovascular and thrombophilic risk factors for central retinal vein occlusion. Eur J Intern Med 2002; 13: 163-9.
• 13 Dahlback B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 1993; 90: 1004-8.
• 14 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
• 15 Albisinni R, Coppola A, Loffredo M. et al. Retinal vein occlusion and inherited conditions predisposing to thrombophilia. Thromb Haemost 1998; 80: 702-3.
• 16 Glueck CJ, Bell H, Vadlamani L. et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol 1999; 117: 43-9.
• 17 Greiner K, Peetz D, Winkgen A. et al. Genetic thrombophilia in patients with retinal vascular occlusion. Int Ophthalmol 1999; 23: 155-60.
• 18 Greiner K, Hafner G, Dick B. et al. Retinal vascular occlusion and deficiencies in the protein C pathway. Am J Ophthalmol 1999; 128: 69-74.
• 19 Kuhli C, Hattenbach LO, Scharrer I. et al. High prevalence of resistance to APC in young patients with retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 163-8.
• 20 Marcucci R, Bertini L, Giusti B. et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86: 772-6.
• 21 Graham SL, Goldberg I, Murray B. et al. Activated protein C resistance–low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust N Z J Ophthalmol 1996; 24: 199-205.
• 22 Linna T, Ylikorkala A, Kontula K. et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997; 77: 214-6.
• 23 Salomon O, Moisseiev J, Rosenberg N. et al. Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinolysis 1998; 9: 617-22.
• 24 Kalayci D, Gurgey A, Guven D, Parlak H, Hasiripi H. Factor V Leiden and prothrombin 20210 A mutations in patients with central and branch retinal vein occlusion. Acta Ophthalmol Scand 1999; 77: 622-4.
• 25 Lahey JM, Tunc M, Kearney J. et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. Ophthalmology 2002; 109: 126-31.
• 26 Delahousse B, Arsene S, Piquemal R. et al. The 20210A allele of the prothrombin gene is not a risk factor for retinal vein occlusion. Blood Coagul Fibrinolysis 1998; 9: 447-8.
• 27 Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993; 37: 393-417.
• 28 Quinlan PM, Elman MJ, Bhatt AK. et al. The natural course of central retinal vein occlusion. Am J Ophthalmol 1990; 110: 118-23.
• 29 Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240: 180-96.
• 30 Hayreh SS, Zimmerman MB, Podhajsky P. Incidence of various types of retinal vein occlusion and their recurrence and demographic characteristics. Am J Ophthalmol 1994; 117: 429-41.
• 31 Dodson PM, Kubicki AJ, Taylor KG. et al. Medical conditions underlying recurrence of retinal vein occlusion. Br J Ophthalmol 1985; 69: 493-6.
• 32 Spagnolo BV, Nasrallah FP. Bilateral retinal vein occlusion associated with factor V Leiden mutation. Retina 1998; 18: 377-8.